Mass spectrometry as a tool for biomarkers searching in gynecological oncology

Banach, Paulina; Suchy, Wiktor; Dereziński, Paweł; Matysiak, Jan; Kokot, Zenon J.; Nowak‐Markwitz, Ewa

doi:10.1016/j.biopha.2017.05.146

Cited by 21 publications

(23 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, however, with the advent of new technologies including nextgeneration sequencing and mass spectrometry (MS), an objective and pragmatic approach to biomarker identification using biofluids has come to the fore (32). Potential diagnostic biomarkers must overcome several hurdles before they can be used in the clinical setting: discovery, validation, and verification (32,33). Importantly, the performance of any novel test needs to be evaluated in terms of its analytical performance, clinical validity and clinical utility (Table 1) (34).…”

Section: Biomarker Discovery Validation and Clinical Utilitymentioning

confidence: 99%

“…A wide variety of substances with potential to serve as EC biomarkers can be found in urine and include endogenous metabolites, genetic products such as tumor DNA, peptides/proteins, malignant cells and secreted organelles such as extracellular vesicles (38)(39)(40). The exploration of each of these targets for biomarker identification requires the use of specialized techniques based on platforms such as cytology/single cell technology, spectroscopy, genomics, transcriptomics, proteomics, and metabolomics (33,41,42).…”

Section: Urinary Biomarkers For Ec Detectionmentioning

confidence: 99%

“…Targeted approaches are thus often employed to validate findings obtained from untargeted studies. Two platforms are commonly used in metabolomic biomarker research: MS and nuclear magnetic resonance (NMR) spectroscopy (33,68).…”

Section: Endogenous Urinary Metabolitesmentioning

confidence: 99%

See 2 more Smart Citations

Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer

et al. 2020

View full text Add to dashboard Cite

Endometrial cancer is the most common malignancy of the female genital tract and its incidence is rising in parallel with the mounting prevalence of obesity. Early diagnosis has great potential to improve outcomes as treatment can be curative, especially for early stage disease. Current tests and procedures for diagnosis are limited by insufficient accuracy in some and unacceptable levels of invasiveness and discomfort in others. There has, therefore, been a growing interest in the search for sensitive and specific biomarkers for endometrial cancer detection based on non-invasive sampling methodologies. Urine, the prototype non-invasive sample, is attractive for biomarker discovery as it is easily accessible and can be collected repeatedly and in quantity. Identification of urinary biomarkers for endometrial cancer detection relies on the excretion of systemic biomarkers by the kidneys or urinary contamination by biomarkers shed from the uterus. In this review, we present the current standing of the search for endometrial cancer urinary biomarkers based on cytology, genomic, transcriptomic, proteomic, and metabolomic platforms. We summarize the biomarker candidates and highlight the challenges inherent in urinary biomarker discovery. We review the various technologies with promise for biomarker detection and assess these novel approaches for endometrial cancer biomarker research.

show abstract

Section: Biomarker Discovery Validation and Clinical Utilitymentioning

confidence: 99%

Section: Urinary Biomarkers For Ec Detectionmentioning

confidence: 99%

See 1 more Smart Citation

Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer is a common type of malignancy, and also the main cause of gynecological cancer mortality ( 1 ). Due to the location of the ovaries, there are no notable symptoms in the early stage of carcinogenesis ( 2 ). The majority of patients are diagnosed with advanced-stage ovarian cancer, with the symptoms including an abdominal mass, ascites and notable weight loss ( 3 ).…”

Section: Introductionmentioning

confidence: 99%

Naringin inhibits ovarian tumor growth by promoting apoptosis: An inï¿½vivo study

Cai

Hai-xia

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

The aim of the present study was to investigate the antitumor activities of naringin in ovarian cancer, and to assess the underlying mechanisms. Ovarian tumor cells were implanted into nude mice to produce ovarian tumors in vivo. The mice were divided into six groups: Control, low dose naringin [0.5 mg/kg, intraperitoneal (i.p.)], middle dose naringin (1 mg/kg, i.p.), high dose naringin (2 mg/kg, i.p.), positive control (cisplatin, 2 mg/kg, i.p.) and a combination of cisplatin and naringin (both 2 mg/kg). Following administration of naringin and/or cisplatin, the tumor size and weight were measured. Apoptosis of tumor cells was detected using a terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Apoptosis-associated gene expression was detected using reverse transcription-polymerase chain reaction and immunohistochemistry. In the range of 0.5–2 mg/kg, naringin dose-dependently inhibited tumor growth, as demonstrated by a decrease in tumor size and weight. Naringin promoted apoptosis of the ovarian tumor cells. Additionally, naringin reduced the expression of B-cell lymphoma (Bcl)-2, Bcl-extra large (Bcl-xL), cyclin D1, c-Myc and survivin, while it increased the expression of caspase-3 and caspase-7. The data demonstrated that naringin inhibited ovarian tumor growth in vivo. Its mechanisms may be associated with caspase-7-, caspase-3-, Bcl-2- and Bcl-xL-mediated apoptosis. Nevertheless, the clinical application of naringin in the treatment of ovarian cancer requires further study.

show abstract

“…The platforms commonly used in endometrial cancer metabolomic studies are liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance spectroscopy (NMR) ( Figure 1) [51,52]. LC-MS deals with the ionisation of chromatographically separated analytes and their subsequent identification based on their mass-to-charge ratio and chromatographic retention time [53,54]. Metabolites that ionise efficiently are thus more easily identifiable by MS [55].…”

Section: Metabolomic Platforms For Ec Biomarker Researchmentioning

confidence: 99%

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer

et al. 2020

View full text Add to dashboard Cite

Metabolic reprogramming is increasingly recognised as one of the defining hallmarks of tumorigenesis. There is compelling evidence to suggest that endometrial cancer develops and progresses in the context of profound metabolic dysfunction. Whilst the incidence of endometrial cancer continues to rise in parallel with the global epidemic of obesity, there are, as yet, no validated biomarkers that can aid risk prediction, early detection, prognostic evaluation or surveillance. Advances in high-throughput technologies have, in recent times, shown promise for biomarker discovery based on genomic, transcriptomic, proteomic and metabolomic platforms. Metabolomics, the large-scale study of metabolites, deals with the downstream products of the other omics technologies and thus best reflects the human phenotype. This review aims to provide a summary and critical synthesis of the existing literature with the ultimate goal of identifying the most promising metabolite biomarkers that can augment current endometrial cancer diagnostic, prognostic and recurrence surveillance strategies. Identified metabolites and their biochemical pathways are discussed in the context of what we know about endometrial carcinogenesis and their potential clinical utility is evaluated. Finally, we underscore the challenges inherent in metabolomic biomarker discovery and validation and provide fresh perspectives and directions for future endometrial cancer biomarker research.

show abstract

Mass spectrometry as a tool for biomarkers searching in gynecological oncology

Cited by 21 publications

References 58 publications

Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer

Urinary Biomarkers and Their Potential for the Non-Invasive Detection of Endometrial Cancer

Naringin inhibits ovarian tumor growth by promoting apoptosis: An inï¿½vivo study

Metabolomic Biomarkers for Detection, Prognosis and Identifying Recurrence in Endometrial Cancer

Contact Info

Product

Resources

About